IPP Bureau
Vimta Labs posts Q4 FY25 PAT at Rs. 18.31 Cr
By IPP Bureau - May 01, 2025
Vimta Labs has reported total income of Rs. 96.08 crores during the period ended March 31, 2025
Sigachi Industries signs MoU with Respilon Group
By IPP Bureau - May 01, 2025
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
USFDA inspects Marksans’s subsidiary Time-Cap Laboratories' manufacturing facility
By IPP Bureau - May 01, 2025
The Subsidiary has received one inspectional observation in Form 483
Strides receives USFDA approval for anti-inflammatory Celecoxib Capsules
By IPP Bureau - May 01, 2025
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
By IPP Bureau - May 01, 2025
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals
By IPP Bureau - May 01, 2025
Alembic Pharmaceuticals commissions new facility at Pithampur
Dr. Morepen launches Rs. 499 annual multivitamin pack on Labour’s Day
By IPP Bureau - May 01, 2025
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Aster DM Healthcare completes acquisition of 5% stake in Quality Care India
By IPP Bureau - May 01, 2025
The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow
Gland Pharma receives USFDA approval for Latanoprostene Bunod Ophthalmic Solution
By IPP Bureau - May 01, 2025
This Product is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Medanta to set up a 400-bed super specialty hospital in Guwahati
By IPP Bureau - April 30, 2025
The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
ekincare raises investment from MSD IDEA Studio Asia Pacific
By IPP Bureau - April 30, 2025
ekincare has raised a total funding of $22M since 2015 till date
Indegene posts Q4 FY25 consolidated PAT at Rs. 117.6 Cr
By IPP Bureau - April 29, 2025
The company has posted net profit of Rs. 406.7 crores for the Financial Year ended March 31, 2025
Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
By IPP Bureau - April 29, 2025
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
IOL Chemicals and Pharmaceuticals receives approval CDE of NMPA, China for Ibuprofen
By IPP Bureau - April 29, 2025
This approval authorizes the company to export Ibuprofen to the Chinese markets
Closure of USFDA inspection at Zydus' API Unit at Dabhasa, Gujarat
By IPP Bureau - April 29, 2025
The inspection concluded with 6 observations and none of them were related to Data Integrity
